These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

491 related items for PubMed ID: 22780962

  • 1. Predictors of placebo response in adults with attention-deficit/hyperactivity disorder: data from 2 randomized trials of osmotic-release oral system methylphenidate.
    Buitelaar JK, Sobanski E, Stieglitz RD, Dejonckheere J, Waechter S, Schäuble B.
    J Clin Psychiatry; 2012 Aug; 73(8):1097-102. PubMed ID: 22780962
    [Abstract] [Full Text] [Related]

  • 2. Predictors of treatment outcome in adults with ADHD treated with OROS® methylphenidate.
    Buitelaar JK, Kooij JJ, Ramos-Quiroga JA, Dejonckheere J, Casas M, van Oene JC, Schäuble B, Trott GE.
    Prog Neuropsychopharmacol Biol Psychiatry; 2011 Mar 30; 35(2):554-60. PubMed ID: 21185347
    [Abstract] [Full Text] [Related]

  • 3. Correlation of symptomatic improvements with functional improvements and patient-reported outcomes in adults with attention-deficit/hyperactivity disorder treated with OROS methylphenidate.
    Rösler M, Ginsberg Y, Arngrim T, Adamou M, Niemelä A, Dejonkheere J, van Oene J, Schäuble B.
    World J Biol Psychiatry; 2013 May 30; 14(4):282-90. PubMed ID: 21517701
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, double-blind, parallel group, dose-escalation study.
    Adler LA, Zimmerman B, Starr HL, Silber S, Palumbo J, Orman C, Spencer T.
    J Clin Psychopharmacol; 2009 Jun 30; 29(3):239-47. PubMed ID: 19440077
    [Abstract] [Full Text] [Related]

  • 5. Does OROS-methylphenidate improve core symptoms and deficits in executive function? Results of an open-label trial in adults with attention deficit hyperactivity disorder.
    Fallu A, Richard C, Prinzo R, Binder C.
    Curr Med Res Opin; 2006 Dec 30; 22(12):2557-66. PubMed ID: 17166338
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and safety of prolonged-release OROS methylphenidate in adults with attention deficit/hyperactivity disorder: a 13-week, randomized, double-blind, placebo-controlled, fixed-dose study.
    Casas M, Rösler M, Sandra Kooij JJ, Ginsberg Y, Ramos-Quiroga JA, Heger S, Berwaerts J, Dejonckheere J, van der Vorst E, Schäuble B.
    World J Biol Psychiatry; 2013 May 30; 14(4):268-81. PubMed ID: 22106853
    [Abstract] [Full Text] [Related]

  • 7. A randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of osmotic-controlled release oral delivery system methylphenidate HCl in adults with attention-deficit/hyperactivity disorder in Japan.
    Takahashi N, Koh T, Tominaga Y, Saito Y, Kashimoto Y, Matsumura T.
    World J Biol Psychiatry; 2014 Aug 30; 15(6):488-98. PubMed ID: 24456065
    [Abstract] [Full Text] [Related]

  • 8. A randomized, placebo-controlled trial of three fixed dosages of prolonged-release OROS methylphenidate in adults with attention-deficit/hyperactivity disorder.
    Medori R, Ramos-Quiroga JA, Casas M, Kooij JJ, Niemelä A, Trott GE, Lee E, Buitelaar JK.
    Biol Psychiatry; 2008 May 15; 63(10):981-9. PubMed ID: 18206857
    [Abstract] [Full Text] [Related]

  • 9. Twenty-four-week treatment with extended release methylphenidate improves emotional symptoms in adult ADHD.
    Rösler M, Retz W, Fischer R, Ose C, Alm B, Deckert J, Philipsen A, Herpertz S, Ammer R.
    World J Biol Psychiatry; 2010 Aug 15; 11(5):709-18. PubMed ID: 20353312
    [Abstract] [Full Text] [Related]

  • 10. Functional improvement and correlations with symptomatic improvement in adults with attention deficit hyperactivity disorder receiving long-acting methylphenidate.
    Buitelaar JK, Casas M, Philipsen A, Kooij JJ, Ramos-Quiroga JA, Dejonckheere J, van Oene JC, Schäuble B.
    Psychol Med; 2012 Jan 15; 42(1):195-204. PubMed ID: 21733214
    [Abstract] [Full Text] [Related]

  • 11. Predictors and impact of non-adherence in adults with attention-deficit/hyperactivity disorder receiving OROS methylphenidate: results from a randomized, placebo-controlled trial.
    Kooij JJ, Rösler M, Philipsen A, Wächter S, Dejonckheere J, van der Kolk A, van Agthoven M, Schäuble B.
    BMC Psychiatry; 2013 Jan 24; 13():36. PubMed ID: 23347693
    [Abstract] [Full Text] [Related]

  • 12. Multisite controlled study of OROS methylphenidate in the treatment of adolescents with attention-deficit/hyperactivity disorder.
    Wilens TE, McBurnett K, Bukstein O, McGough J, Greenhill L, Lerner M, Stein MA, Conners CK, Duby J, Newcorn J, Bailey CE, Kratochvil CJ, Coury D, Casat C, Denisco MJ, Halstead P, Bloom L, Zimmerman BA, Gu J, Cooper KM, Lynch JM.
    Arch Pediatr Adolesc Med; 2006 Jan 24; 160(1):82-90. PubMed ID: 16389216
    [Abstract] [Full Text] [Related]

  • 13. A randomized, double-blind, placebo-controlled, multicenter study evaluating the efficacy, safety, and tolerability of extended-release metadoxine in adults with attention-deficit/hyperactivity disorder.
    Manor I, Ben-Hayun R, Aharon-Peretz J, Salomy D, Weizman A, Daniely Y, Megiddo D, Newcorn JH, Biederman J, Adler LA.
    J Clin Psychiatry; 2012 Dec 24; 73(12):1517-23. PubMed ID: 23290324
    [Abstract] [Full Text] [Related]

  • 14. Atomoxetine treatment in adults with attention-deficit/hyperactivity disorder and comorbid social anxiety disorder.
    Adler LA, Liebowitz M, Kronenberger W, Qiao M, Rubin R, Hollandbeck M, Deldar A, Schuh K, Durell T.
    Depress Anxiety; 2009 Dec 24; 26(3):212-21. PubMed ID: 19194995
    [Abstract] [Full Text] [Related]

  • 15. Long-term efficacy and safety outcomes with OROS-MPH in adults with ADHD.
    Buitelaar JK, Trott GE, Hofecker M, Waechter S, Berwaerts J, Dejonkheere J, Schäuble B.
    Int J Neuropsychopharmacol; 2012 Feb 24; 15(1):1-13. PubMed ID: 21798108
    [Abstract] [Full Text] [Related]

  • 16. Does placebo response differ between objective and subjective measures in children with attention-deficit/hyperactivity disorder?
    Sumner CR, Haynes VS, Teicher MH, Newcorn JH.
    Postgrad Med; 2010 Sep 24; 122(5):52-61. PubMed ID: 20861588
    [Abstract] [Full Text] [Related]

  • 17. Personality disorders in ADHD Part 2: The effect of symptoms of personality disorder on response to treatment with OROS methylphenidate in adults with ADHD.
    Robison RJ, Reimherr FW, Gale PD, Marchant BK, Williams ED, Soni P, Halls C, Strong RE.
    Ann Clin Psychiatry; 2010 May 24; 22(2):94-102. PubMed ID: 20445836
    [Abstract] [Full Text] [Related]

  • 18. OROS-methylphenidate efficacy on specific executive functioning deficits in adults with ADHD: a randomized, placebo-controlled cross-over study.
    Bron TI, Bijlenga D, Boonstra AM, Breuk M, Pardoen WF, Beekman AT, Kooij JJ.
    Eur Neuropsychopharmacol; 2014 Apr 24; 24(4):519-28. PubMed ID: 24508533
    [Abstract] [Full Text] [Related]

  • 19. Efficacy of a novel biphasic controlled-release methylphenidate formula in adults with attention-deficit/hyperactivity disorder: results of a double-blind, placebo-controlled crossover study.
    Jain U, Hechtman L, Weiss M, Ahmed TS, Reiz JL, Donnelly GA, Harsanyi Z, Darke AC.
    J Clin Psychiatry; 2007 Feb 24; 68(2):268-77. PubMed ID: 17335326
    [Abstract] [Full Text] [Related]

  • 20. Better efficacy for the osmotic release oral system methylphenidate among poor adherents to immediate-release methylphenidate in the three ADHD subtypes.
    Chou WJ, Chou MC, Tzang RF, Hsu YC, Gau SS, Chen SJ, Wu YY, Huang YF, Liang HY, Cheng H.
    Psychiatry Clin Neurosci; 2009 Apr 24; 63(2):167-75. PubMed ID: 19335386
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.